Most pharmaceutical companies that patients know by name make the drugs they see on pharmacy shelves. Suven Pharmaceuticals does something different — it makes the molecules that go into other companies’ drugs. As a contract development and manufacturing organisation, Suven has spent more than three decades building the chemistry capabilities that global drug discoverers depend on, from early-stage intermediates for new chemical entities to commercial-scale active pharmaceutical ingredients.
When a global pharmaceutical company discovers a promising new molecule, it faces a fundamental question: build the chemistry in-house, or find a partner who can do it better, faster, and at lower cost? For dozens of innovator companies around the world, the answer has been Suven.
The company’s roots trace to 1989, when Suven Life Sciences was founded in Hyderabad by Venkateswarlu Jasti with a focus on central nervous system drug discovery. Over the following decades, the company built deep process chemistry capabilities — the ability to take a laboratory-scale synthesis and engineer it into a commercially viable manufacturing process. In 2020, the CDMO business was demerged into a separate entity, Suven Pharmaceuticals, to give investors clearer exposure to the contract manufacturing opportunity.
The CDMO model is inherently different from traditional generic manufacturing. Rather than competing on price to make copies of existing drugs, CDMOs compete on chemistry — solving difficult synthesis problems that innovator companies cannot solve themselves, or choose not to. The margins are typically higher, the relationships are longer, and the intellectual property belongs to the client. Suven’s role is to be indispensable, not visible.
In December 2022, Advent International — one of the world’s largest private equity firms with a strong track record in healthcare — acquired a controlling stake in Suven Pharmaceuticals for approximately $763 million from the Jasti family. The transaction was one of the largest private equity investments in an Indian CDMO.
Under Advent’s ownership, Suven accelerated its transformation from a single-modality CDMO into a diversified chemistry platform. The company acquired Casper Pharma in 2022, took a 67.5% stake in Sapala Organics in 2024 to add oligonucleotide intermediate capabilities, and made a strategic 56% investment in US-based NJ Bio in late 2024 to enter the antibody-drug conjugate development space — one of the fastest-growing segments in pharmaceutical manufacturing.
In February 2024, Suven announced a merger with Cohance Lifesciences, a specialty chemicals and pharmaceutical CDMO with complementary capabilities. The merger became effective on May 1, 2025, creating a combined entity with proforma revenue of approximately $288 million and a pathway to $1 billion in revenue within five years. The merged entity now operates under the name Cohance Lifesciences Limited.
What distinguishes Suven in the CDMO landscape is the breadth of its chemistry toolkit. The company has moved beyond traditional small-molecule intermediates into emerging drug modalities that represent the future of pharmaceutical manufacturing. With the Pharma CDMO segment generating approximately 62% of FY 2025 revenue, the company’s technical capabilities are the core of its competitive position.
Suven operates primarily across India, the United States, and Europe. In India, the company supplies bulk drugs, intermediates, fine chemicals, and CDMO services. In the US and European markets, the focus is on intermediates, advanced intermediates, and contract services for innovator pharmaceutical companies developing new chemical entities. The company’s EBITDA margins have consistently exceeded 40%, reflecting the high-value nature of its chemistry-driven services.
Clients span India, the United States, and Europe
Suven operates multiple manufacturing facilities across Telangana and Andhra Pradesh, with capabilities spanning kilo-lab scale through commercial production. The company’s research and development centre supports process chemistry, analytical development, and technology transfer for global clients. Following the merger with Cohance, the combined entity operates additional facilities that extend its manufacturing footprint and technical capabilities, including sites in Gujarat and Maharashtra.
Sources: Suven Pharmaceuticals Annual Reports FY2022–23 and FY2023–24. Suven Pharmaceuticals Investor Presentations. Advent International press releases and SEC filings. BSE India corporate filings. Indian patent office records.